The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.

Xingdi HuKingsley P WildmanSubham BasuPeggy L LinClare RowntreeVaskar Saha

Published in: Health economics review (2019)

UKALL 2011, EudraCT number 2010-020924-22; UKALL 2003, EudraCT number 2007-004013-34; UKALL14, EudraCT number 2009-012717-22.

Keyphrases